Functional Fungi and Microdosing for Optimal Wellbeing with Alli Schaper, Into The Multiverse
Functional mushrooms for health: what they are, why they’re important, and what benefits they provide.
Similar Posts
The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)
In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.
In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?
The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?
Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.
Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.
It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.
James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.
In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Cybin #Psilocybin #Psychedelics
Can Psychedelics Heal Trauma by Regulating the Nervous System?
Can psychedelics heal trauma? The use of psychedelics can play a significant role in supporting the processing and healing of trauma by regulating the nervous system simultaneously.
Are Celebrities Helping the Psychedelic Movement?
To watch the entire Spotlight In Focus episode, visit: https://www.altrd.tv/shows/spotlight-focus/season/1/episode/2…
The Growing Trend of Moms Who Microdose
The constant stress of motherhood can lead to chronic depression and burnout, but these UK moms who microdose think they have found the solution
Why I’m More Excited About MindMed’s 18-MC than its LSD treatments
Happy Holidays guys! I 🎄🙃 In this episode we’ll cover the many reasons why I’m more excited about MindMed’s 18-MC than its LSD treatments. As I mentioned in my previous video, the unfortunate fact is that the world is dealing with a second hidden epidemic: The Opioid Crisis. MindMed ( MMED/ MMEDF ) has a solution: 18-MC. Yes, MindMed has a diverse pipeline with other experiential drugs such as LSD for anxiety and psilocybin to treat ADHD. However, this psychedelic medicines company has its own proprietary compound (18-MC) to treat addiction which, if successful, cannot be copied by the upcoming competition. Keep watching to learn more about MindMed’s plan to end the opioid crisis with 18-MC. We may have a light at the end of the tunnel, and MindMed could potentially defeat the opioid epidemic threat, making MMED one of the best stocks for 2021.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
#mindmedstock